1704-P: Coexistence of Hypoadiponectinemia and Impaired Adipose Tissue Insulin Sensitivity Increases the Risk of Metabolic Abnormality Due to Muscle Insulin Resistance in Nonobese Japanese Men

Abstract

Both reduced circulating adiponectin (AN) and impaired adipose tissue insulin sensitivity (ATIS) are observed in obese subjects with insulin resistance (IR). While Asians easily develop metabolic disease featured with IR without obesity, we found that both reduced AN and impaired ATIS are individually associated with muscle IR and accumulation of intrahepatic lipid (IHL) in non-obese Japanese men. However, it is entirely unclear whether the coexistence of reduced AN and impaired ATIS is associated with metabolic abnormality.To clarify this, we studied 94 non-obese Japanese men. We evaluated tissue specific insulin sensitivity by 2-step hyperinsulinemic euglycemic clamp and calculated ATIS as a degree of insulin-mediated suppression of circulating free fatty acid. IHL was measured by 1H-MRS. Then, we divided the subjects into 4 groups based on their median AN and ATIS and assessed the effect of AN and ATIS on the parameters related to muscle IR. As shown in Figure, the levels of IHL in the patients with both reduced AN and impaired ATIS were higher than other groups. The similar tendency was also observed regarding the serum triglyceride level and muscle IR. These results suggested that coexistence of reduced AN and impaired ATIS increases the risk of metabolic abnormality due to muscle IR in non-obese Japanese men. Disclosure M. Kiya: None. Y. Tamura: Advisory Panel; Self; Astellas Pharma Inc. Research Support; Self; Kowa Company, Ltd. Speaker’s Bureau; Self; Novo Nordisk Inc., Ono Pharmaceutical Co., Ltd. K. Takeno: None. Y. Someya: None. S. Kakehi: None. M. Sato: None. N. Yamasaki: None. S. Kadowaki: None. R. Suzuki: None. Y. Furukawa: None. D. Sugimoto: None. H. Kaga: None. T. Funayama: None. H. Satoh: None. R. Kawamori: None. H. Watada: Advisory Panel; Self; Abbott, Ajinomoto, Astellas Pharma Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Fuji Film, Janssen Pharmaceuticals, Inc., Kowa Company, Ltd., Kyowa Hakko Kirin Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Inc., Ono Pharmaceutical Co., Ltd., Sanofi-Aventis, Takeda Pharmaceutical Company Limited, Terumo Medical Corporation. Research Support; Self; Astellas Pharma Inc., Bayer Yakuhin, Ltd., Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Eli Lilly Japan K.K., Kissei Pharmaceutical Co., Ltd., Kowa Company, Ltd., Kyowa Hakko Kirin Co., Ltd., Merck Sharp & Dohme Corp., Mitsubishi Tanabe Pharma Corporation, Novartis Pharma K.K., Novo Nordisk Inc., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Sanofi-Aventis, Sanwa Kagaku Kenkyusho, Shionogi & Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Teijin Pharma Limited, Yakult. Speaker’s Bureau; Self; Astellas Pharma Inc., AstraZeneca, Bayer Yakuhin, Ltd., Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Eli Lilly Japan K.K., Kissei Pharmaceutical Co., Ltd., Kowa Company, Ltd., Kyowa Hakko Kirin Co., Ltd., Merck Sharp & Dohme Corp., Mitsubishi Tanabe Pharma Corporation, Novartis Pharmaceuticals Corporation, Novo Nordisk Inc., Ono Pharmaceutical Co., Ltd., Sanofi-Aventis, Sanwa Kagaku Kenkyusho, Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Limited. Funding High Technology Research Center; Strategic Research Foundation at Private Universities; Japan Ministry of Education, Culture, Sports, Science and Technology (23680069, 26282197, 17K19929); Japan Diabetes Foundation; Suzuken Memorial Foundation; Mitsukoshi Welfare Foundation; Diabetes Masters Conference